{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of CI was not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"22.51","upperLimit":"NA","value":"26.0"},{"comment":"The upper limit of CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"17.77","upperLimit":"NA","value":"21.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"281"},{"groupId":"OG001","value":"252"}],"units":"Participants"}],"description":"DOR was measured as the time in months from the date of first documentation of a confirmed response of PR or better (CR \\[including sCR\\] + PR+ VGPR) to the date of the first documented disease progression (PD) among participants who responded to the treatment. Response was assessed by the investigator using International Myeloma Working Group (IMWG) Criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"Response-Evaluable population included all participants who received at least 1 dose of study drug, had measurable disease at baseline, and at least 1 post-baseline response assessment. Overall number analyzed is the number of participants available for analysis.","reportingStatus":"POSTED","timeFrame":"Day 1 of each cycle (every 4 weeks) until disease progression up to approximately 38 months","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}